In a statement, the firm's President and CEO Zhenya Lindgardt noted that in 2025 Sera pivoted from clinical validation to commercial operation.
S, progesterone, 17-hydroxyprogesterone and androstenedione, and run on Roche's cobas i 601 mass spectrometer.
Altai Capital Management has demanded the appointment of two Altai candidates to OraSure's board and urged a strategic review and possible company sale.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results